Showing 4431-4440 of 10058 results for "".
- FDA Approves Once-Daily Oral Semaglutidehttps://practicaldermatology.com/news/fda-approves-once-daily-oral-semaglutide/2485258/The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-daily oral formulation of semaglutide, marketed as Wegovy® pill, marking the first oral GLP-1 receptor agonist approved for chronic weight management in the United States. The approval includes indications for adults with
- MEK Inhibition Shows Promise in Aggressive EB-Linked Skin Cancershttps://practicaldermatology.com/news/mek-inhibition-shows-promise-in-aggressive-eb-linked-skin-cancers/2485197/A transcriptome-driven drug repurposing strategy has identified selumetinib as a potential therapeutic candidate for aggressive squamous cell carcinomas (SCCs) arising in recessive dystrophic epidermolysis bullosa (RDEB). Resea
- Analysis Suggests Possible 'Oral–Gut–Skin Axis' in HShttps://practicaldermatology.com/news/analysis-suggests-possible-oralgutskin-axis-in-hs/2485169/New microbiome research comparing acne and hidradenitis suppurativa (HS) across multiple anatomical sites shows unique microbial signatures that may aid researchers in explaining the chronic HS phenotype. The study authors ana
- FDA: Most PFAS in Cosmetics Lack Adequate Safety Datahttps://practicaldermatology.com/news/fda-most-pfas-in-cosmetics-lack-adequate-safety-data/2485144/The U.S. Food and Drug Administration (FDA) announced that it has released its first congressionally mandated report under the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), assessing the use and safety of perfluoroalkyl and polyfluoroalkyl substances (PF
- Discrimination, Language Gaps Undermine HS Care for Latine Adults: Analysishttps://practicaldermatology.com/news/latine-patients-with-hs-face-barriers-in-pain-and-wound-care-study-finds-discrimination-language-gaps-undermine-hs-care-for-latine-adults/2485130/Latine patients with hidradenitis suppurativa (HS) continue to face barriers to care, according to a qualitative study published in JAMA Dermatology. Study researchers analyzed transcripts from semistructured interviews
- Systematic Review Suggests Anti-Inflammatory Effects of Astragalus membranaceushttps://practicaldermatology.com/news/systematic-review-shows-anti-inflammatory-effects-of-astragalus-membranaceus/2485129/A new systematic review suggests the traditional botanical Astragalus membranaceus may have clinically relevant anti-aging benefits. "The demand for cosmetic strategies to mitigate [skin ag
- Study: Gut Permeability Biomarker Linked with AD Symptom Reliefhttps://practicaldermatology.com/news/study-gut-permeability-biomarker-linked-with-ad-symptom-relief/2485110/New research suggests serum D-lactate levels may predict clinical response to washed microbiota transplantation (WMT), showing the role of intestinal barrier dysfunction in atopic dermatitis (AD). Researchers for the prospective
- Acne Incidence Higher with Higher-Dose LNG-IUS, Meta-Analysis Findshttps://practicaldermatology.com/news/acne-incidence-higher-with-higher-dose-lng-ius-meta-analysis-finds/2485045/A new systematic review and meta-analysis shows the incidence of acne among users of the levonorgestrel-releasing intrauterine system (LNG-IUS), identifying both dosage and age as influential factors. The review included nine ra
- Contact Dermatitis, Unlabeled Ingredients Among Concerns in Self-Tannershttps://practicaldermatology.com/news/contact-dermatitis-unlabeled-ingredients-among-concerns-in-self-tanners/2485034/A recent review in the Journal of Drugs in Dermatology raised some concerns regarding ingredient safety and adverse reactions. Researchers on the study analyzed the top 50 best-selling sunless tanning products on Amazon
- Most Insurers Cover Botulinum Toxin for Axillary Hyperhidrosis: Analysishttps://practicaldermatology.com/news/most-insurers-cover-botulinum-toxin-for-axillary-hyperhidrosis-analysis/2484933/A new cross-sectional study published in the Journal of Drugs in Dermatology finds that while botulinum toxin is broadly covered by private insurers for the treatment of primary axillary hyperhidrosis, access barriers due to